TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

1.309 Zollner-Schwetz I et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin Infect Dis
2008;47:e74-8.
1.310 Guerrant RL et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis
2001;32:331-50.
1.311 DuPont HL. Bacterial diarrhea. N Engl J Med 2009;361:1560-9.
1.312 Musher DM et al. Contagious gastro-intestinal infections. N Engl J Med 2004;351:2417-27.
1.313 Thielman NM et al. Acute infectious diarrhea. N Engl J Med 2004;350:38-47.
1.314 O‘Ryan M et al. An update on management of severe acute infectious gastroenteritis in children. Expert
Rev Anti Infect Ther 2010;8:671-82.
1.315 Phavichitr N et al. Acute gastroenteritis in children: what role for antibacterials? Pediatr Drugs 2003;
5:279-90.
1.316 Dennehy PH. Acute diarrheal disease in children: epidemiology, prevention, and treatment. Infect Dis
Clin North Am 2005;19:585-602.
1.317 Chao HC et al. Bacterial enteric infections in children: etiology, clinical manifestations and antimicrobial
therapy. Expert Rev Anti Infect Ther 2006;4:629-38.
1.318 Elliott EJ. Acute gastroenteritis in children. Br Med J 2007;334:35-40.
1.319 Barclay AR et al. Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol
Nutr 2007;45:569-76.
1.320 Moss RL et al. Laparatomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N
Engl J Med 2006;354:2225-34.
1.321 Flake AW. Necrotizing enterocolitis in preterm infants. Is laparatomy necessary? N Engl J Med 2006;
354:2275-76.
1.322 Sears CL et al. Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea.
Clin Infect Dis 2008;47:797-803.
1.323 Tribble DR et al. Traveler‘s diarrhea in Thailand: randomized, double-blind trial comparing single-dose
and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007;
44:338-46.
1.324 DuPont HL. Azithromycin for the self-treatment of traveler‘s diarrhea. Clin Infect Dis 2007;44:347-9.
1.325 Shlim DR. Update in traveler‘s diarrhea. Infect Dis Clin North Am 2005;19:137-49.
1.326 Diemert DJ. Prevention and self-treatment of traveler‘s diarrhea. Clin Microbiol Rev 2006;19:583-94.
1.327 DuPont HL. Therapy for and prevention of traveler‘s diarrhea. Clin Infect Dis 2007;45(suppl. 1):S78-
84.
1.328 Sanders JW et al. Azithromycin and loperamide are similar to levofloxacin and loperamide for the
treatment of traveler‘s diarrhea in military personnel in Turkey. Clin Infect Dis 2007;45:294-301.
1.329 Okhuysen PC. Current concepts in traveler‘s diarrhea: epidemiology, antimicrobial resistance and
treatment. Curr Opin Infect Dis 2005;18:522-6.
1.330 Leggat PA et al. Thavellers‘ diarrhoea: health advice for travellers. Travel Med Infect Dis 2004;2:17-
22.
1.331 Koo HL et al. Current and future developments in traveler‘s diarrhea therapy. Expert Rev Anti Infect
Ther 2006;4:417-27.
1.332 Yates J. Traveler‘s diarrhea. Am Fam Physician 2005;71:2095-100.
1.333 Al-Abri SS et al. Traveller‘s diarrhoea. Lancet Infect Dis 2005;5:349-60.
1.334 Adachi JA et al. Empirical antimicrobial therapy for traveler‘s diarrhea. Clin Infect Dis 2000;31:1079-
83.
1.335 Sack DA et al. Cholera. Lancet 2004;363:223-33.
1.336 Kartalija M et al. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin Infect Dis
1999;28:701-7.
1.337 Peghini PL et al. Improvement of chronic diarrhea after treatment for intestinal spirochetosis. Dig Dis
Sci 2000;45:1006-10.
1.338 Brooke CJ et al. In vitro antimicrobial susceptibility of Brachyspira pilosicoli isolates from humans. Antimicrob
Agents Chemother 2003;47:2354-7.
1.339 Koteish A et al. Colonic spirochetosis in children and adults. Am J Clin Pathol 2003;120:828-32.
1.340 Evans MR et al. Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter
infection. Clin Infect Dis 2009;48:1500-6.
1.341 Ternhag A et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused
by infection with Campylobacter species. Clin Infect Dis 2007;44:696-700.
1.342 Ruiz-Palacios GM. The health burden of Campylobacter infection and the impact of antimi-crobial
resistance: playing chicken. Clin Infect Dis 2007;44:701-3.
1.343 Lecuit M et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N
Engl J Med 2004;350:239-48.
1.344 Feodoroff FB et al. Severe diarrhoea caused by highly ciprofloxacin-susceptible Campylobacter isolates.
Clin Microbiol Infect 2009;15:188-92.
1.345 Rogers TJ et al. Therapeutic strategies for shigatoxin-producing Escherichia coli infections. Expert
Rev Anti Infect Ther 2009;7:683-6.
1.346 Palermos MS et al. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert
Rev Anti Infect Ther 2009;7:697-707.
1.347 Goldwater PN. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic
uremic syndrome. Expert Rev Anti Infect Ther 2007;5:653-63.
1.348 Tarr PI et al. Shiga toxin producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;
365:1073-86.
1.349 Thorpe CM. Shiga toxin producing Escherichia coli infection. Clin Infect Dis 2004;38:1298-303.
1.350 Tzipori S et al. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome.
Clin Microbiol Rev 2004;17:926-41.
1.351 Orth D et al. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.
Expert Rev Anti Infect Ther 2008;6:101-8.
1.352 Majowicz SE et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis
2010;50:882-9.
1.353 Saha D et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006;354:
2452-62.
1.354 Abraham C et al. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
1.355 Eckburg PB et al. The role of microbes in Crohn‘s disease. Clin Infect Dis 2007;44:256-62.
1.356 Collins P et al. Ulcerative colitis: diagnosis and management. Br Med J 2006;333:340-3.
1.357 Feller M et al. Long-term antibiotic treatment for Crohn‘s disease: systematic review and meta-analy-